
Annual report 2025
added 04-18-2026
BioNTech SE EPS Ratio 2011-2026 | BNTX
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio BioNTech SE
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 42.2 | 0.06 | -0.85 | -0.25 | -0.51 | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 42.2 | -0.85 | 8.13 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | ||
|
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | ||
|
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
-0.15 | - | -19.68 % | $ 18.4 M | ||
|
Aptorum Group Limited
APM
|
-0.19 | $ 0.9 | -2.33 % | $ 6.62 M | ||
|
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
1.37 | $ 21.96 | -0.68 % | $ 3.64 B | ||
|
RedHill Biopharma Ltd.
RDHL
|
-0.21 | $ 1.02 | -0.49 % | $ 428 M | ||
|
Allakos
ALLK
|
-2.14 | - | - | $ 28.6 M | ||
|
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | ||
|
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | ||
|
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | ||
|
Aligos Therapeutics
ALGS
|
-2.45 | $ 6.4 | 4.4 % | $ 63.3 M | ||
|
Applied Therapeutics
APLT
|
-1.42 | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | ||
|
Aridis Pharmaceuticals
ARDS
|
-1.62 | - | 17.91 % | $ 11.1 M | ||
|
Avenue Therapeutics
ATXI
|
-0.93 | - | -52.27 % | $ 4.45 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
2.1 | $ 21.41 | 1.9 % | $ 1 B | ||
|
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | ||
|
AstraZeneca PLC
AZN
|
0.08 | - | - | $ 96.9 B | ||
|
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M | ||
|
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-1.11 | - | -2.5 % | $ 5.88 M | ||
|
Kazia Therapeutics Limited
KZIA
|
-0.186 | $ 12.26 | 3.72 % | $ 1.62 B | ||
|
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K | ||
|
BeiGene, Ltd.
BGNE
|
0.2 | - | 0.49 % | $ 251 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-0.78 | $ 4.08 | 0.25 % | $ 436 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-0.13 | $ 23.26 | 1.75 % | $ 2.96 B | ||
|
Cara Therapeutics
CARA
|
-2.46 | - | -3.03 % | $ 260 M | ||
|
Autolus Therapeutics plc
AUTL
|
-1.08 | $ 1.44 | -5.88 % | $ 383 M | ||
|
Aptose Biosciences
APTO
|
-10.4 | - | -45.71 % | $ 1.2 M | ||
|
BioXcel Therapeutics
BTAI
|
-5.73 | $ 1.06 | -3.64 % | $ 12.9 M | ||
|
CASI Pharmaceuticals
CASI
|
-0.27 | - | - | $ 35.4 M | ||
|
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | ||
|
Cabaletta Bio
CABA
|
-2.1 | $ 2.95 | -3.28 % | $ 296 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-5.97 | $ 2.91 | -1.36 % | $ 4.79 M | ||
|
bluebird bio
BLUE
|
-1.93 | - | - | $ 546 M | ||
|
CymaBay Therapeutics
CBAY
|
-0.99 | - | - | $ 3.45 B | ||
|
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B |